Cite
HARVARD Citation
van Vollenhoven, R. et al. (n.d.). S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study. Lupus science & medicine. pp. A28-A29. [Online].